Journal of the American Academy of Dermatology最新文献

{"title":"Risk of Major Adverse Cardiovascular Events and Venous Thromboembolic Events Between Patients With Psoriasis or Psoriatic Arthritis on Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, Interleukin-12/23 Inhibitors and Interleukin-23 Inhibitors: An Emulated Target Trial Analysis.","authors":"Tai-Li Chen, Jing-Yang Huang, Hui-Yun Lin, Yun-Ting Chang, Cheng-Yuan Li, James Cheng-Chung Wei","doi":"10.1016/j.jaad.2024.12.025","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.12.025","url":null,"abstract":"<p><strong>Background: </strong>The risk of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) in patients with psoriatic disease receiving biologics is not fully understood.</p><p><strong>Objective: </strong>This study aimed to investigate whether novel biologic therapies (IL-17, IL-12/23, and IL-23 inhibitors) for biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) are associated with differences in the risks of MACE and VTE compared with those with TNF inhibitors.</p><p><strong>Methods: </strong>An emulated target trial was designed by a nationwide cohort using data from the TriNetX Research Network. Biologic-naïve patients with psoriasis or PsA receiving biologics between 2014 and 2022 were enrolled. Treatment groups were determined by patients' first prescription of biologics. Three propensity-matched cohorts were established, namely, IL-17i vs. TNFi, IL-12/23i vs. TNFi, and IL-23i vs. TNFi. The incidence rate and incidence rate ratios were estimated.</p><p><strong>Results: </strong>A total of 32,098 biologic-naïve patients with psoriasis or PsA treated with biologics were included. All enrollees were further categorized into four cohorts (20,314 in the TNFi cohort, 5,073 in the IL-17i cohort, 3,573 in the IL-12/23i cohort, and 3,138 in the IL-23i cohort). No significant difference in the risks of MACE and VTE between biologics existed among patients with psoriatic disease. In the subgroup analyses for either psoriasis or PsA, no significant difference in the risks of MACE or VTE was noted among all comparisons in the subgroup. Among patients with pre-existing hyperlipidemia and diabetes mellitus, the risks of MACE and VTE among patients using new biologics (IL-17i, IL-12/23i, or IL-23i) were lower than those using TNFi.</p><p><strong>Limitations: </strong>The data lack psoriasis severity.</p><p><strong>Conclusion: </strong>Among patients with psoriasis or PsA, no significant risk differences of MACE and VTE were detected between those with IL-17i, IL-12/23i, IL-23i and those with TNFi. These findings can serve as a reference to healthcare providers and patients when making clinical decisions, thereby also providing evidence for future pharmacovigilance research.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ethics behind treating scars in skin of color research subjects.","authors":"Rebecca L Quiñonez, Jasira Ziglar, Lydiah Fridah M Mpyisi, Tasneem F Mohammad, Iltefat Hamzavi, Henry W Lim","doi":"10.1016/j.jaad.2024.11.074","DOIUrl":"10.1016/j.jaad.2024.11.074","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on the increased risk of hidradenitis suppurativa in patients with human papillomavirus infection.","authors":"Tai-Li Chen, Tsung-Hsien Chang","doi":"10.1016/j.jaad.2024.12.027","DOIUrl":"10.1016/j.jaad.2024.12.027","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials.","authors":"Emma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, Stephan Weidinger, Thomas Bieber, H Chih-Ho Hong, Hany Elmaraghy, Amber Reck Atwater, Evangeline Pierce, Chenjia Xu, Helena Agell, Esther Garcia Gil, Eric Simpson","doi":"10.1016/j.jaad.2024.12.026","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.12.026","url":null,"abstract":"<p><strong>Background: </strong>Lebrikizumab demonstrated statistically significant improvements in patients with moderate-to-severe atopic dermatitis at week 16 with a durable response up to week 52.</p><p><strong>Objective: </strong>To investigate the efficacy of lebrikizumab-treated patients at 52 weeks who did not achieve the ADvocate1 and ADvocate2 protocol-defined response criteria (≥75% improvement in the Eczema Area and Severity Index [EASI 75] or Investigator Global Assessment [IGA] 0/1 with ≥2-point improvement without rescue medication) after 16 weeks.</p><p><strong>Methods: </strong>This analysis includes observed data for patients who received lebrikizumab every 2 weeks during the induction period, did not achieve the protocol-defined response, and subsequently received open-label lebrikizumab treatment.</p><p><strong>Results: </strong>At week 16, 38.1% of lebrikizumab-treated patients entered the escape arm due to not achieving the response criteria. However, most of these patients had achieved ≥50% improvement in EASI (58.1%) by week 16. At week 52, 36.1% achieved IGA 0/1 with ≥2-point improvement, 75.5% achieved EASI 75, 44.2% achieved ≥90% improvement in EASI, and 66.4% reported ≥4-point Pruritus Numeric Rating Scale improvement.</p><p><strong>Limitations: </strong>This analysis assesses patients receiving open-label treatment with concomitant topical therapy allowed.</p><p><strong>Conclusion: </strong>Lebrikizumab-treated patients not achieving the protocol-defined response at week 16 can benefit from the continuation of longer-term therapy.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disability and the Dermatology Patient- Part 2: Supporting Patients with Disabilities.","authors":"Sarah Kamsiah Zemlok, Sonal Muzumdar, Mary Wu Chang, Robert Krug, Brett Sloan","doi":"10.1016/j.jaad.2024.10.123","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.10.123","url":null,"abstract":"<p><p>Dermatologic disease can result in disability. In part two of this continuing medical education (CME) article, we highlight disabilities that may result from dermatologic conditions. We introduce guidelines for caring for patients with disabilities including how to identify, assess, and document patients' disabilities and provide patient-centered care and support.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethical implications of nonphysician clinicians demanding pay parity.","authors":"Timothy Klufas, Ayushya Ajmani, Albert E Zhou, Donna A Aiudi, Jenna R Bordelon Kelsey, Jane M Grant-Kels","doi":"10.1016/j.jaad.2024.12.024","DOIUrl":"10.1016/j.jaad.2024.12.024","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disability and the Dermatology Patient- Part 1: Improving Access to Dermatologic Care.","authors":"Sonal Muzumdar, Sarah Kamsiah Zemlok, Brett Sloan, Robert Krug, Mary Wu Chang","doi":"10.1016/j.jaad.2024.10.122","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.10.122","url":null,"abstract":"<p><p>Disability is common amongst dermatologic patients. Herein, we review the epidemiology of disability and terminology used to refer to patients with disabilities. We discuss different forms of disability, including cognitive, motor, visual and hearing, and review how dermatology practices can better accommodate patients with disabilities to optimize care.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective analysis reveals a decrease in reimbursement of pathology costs while patient out-of-pocket expense has increased.","authors":"Natella Maglakelidze, Ashwath Sampath, Allison Locy, Austin C Cohrs, Thomas N Helm, Galen Foulke, Matthew F Helm","doi":"10.1016/j.jaad.2024.11.069","DOIUrl":"10.1016/j.jaad.2024.11.069","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"North American Clinical Practice Guidelines for the Medical Management of Hidradenitis Suppurativa in Special Patient Populations.","authors":"Raed Alhusayen, Serena Dienes, Megan Lam, Afsaneh Alavi, Ali Alikhan, Maria Aleshin, Emad Bahashwan, Steve Daveluy, Noah Goldfarb, Amit Garg, Wayne Gulliver, Tarannum Jaleel, Alexa B Kimball, Mark G Kirchhof, Joslyn Kirby, Joi Lenczowski, Hadar Lev-Tov, Michelle A Lowes, Irene Lara-Corrales, Robert Micheletti, Martin Okun, Lauren Orenstein, Susan Poelman, Vincent Piguet, Martina Porter, Barry Resnik, Cathryn Sibbald, Vivian Shi, Christopher Sayed, Se Mang Wong, Andrea Zaenglein, Helene Veillette, Jennifer L Hsiao, Haley B Naik","doi":"10.1016/j.jaad.2024.11.071","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.11.071","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist.</p><p><strong>Objective: </strong>To provide evidence-based consensus recommendations for patients with HS in seven special patient populations: i) pregnancy, ii) breastfeeding, iii) pediatrics, iv) malignancy, v) tuberculosis infection, vi) hepatitis B or C infection, and vii) HIV disease.</p><p><strong>Methods: </strong>Recommendations were developed using the Grading of Recommendations Assessment, Development and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process.</p><p><strong>Results: </strong>119 expert consensus statements are provided for the management of patients with HS across these seven special patient populations.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Kang et al, \"Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study\".","authors":"Caitlin A Kearney, Anna L Brinks, Carli D Needle, Jerry Shapiro, Mario E Lacouture, Kristen I Lo Sicco","doi":"10.1016/j.jaad.2024.11.073","DOIUrl":"10.1016/j.jaad.2024.11.073","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}